— Study compared hip fractures after 5 years, 7 years, and 10 years by Kristen Monaco, Staff Writer, MedPage Today December 7, 2020 Women got no extra protection against hip fracture from staying on oral bisphosphonates beyond 7 years, researchers reported. In a retrospective cohort study of nearly 30,000 women who completed 5 years of […]
William C. Ou; Charles C. Wykoff, MD, PhD September 23, 2016 Bisphosphonates: A Staple of Osteoporosis Treatment Osteoporosis is a disease characterized by weak and brittle bones that affects 10 million Americans over the age of 50 years and leads to 1.5 million bone fractures annually in the United States.[1,2] Several mechanisms can underlie this […]
May 17, 2016 American Journal of Ophthalmology TAKE-HOME MESSAGE The analysis of databases from the British Columbia Ministry of Health and the FDA Adverse Event Reporting System found an increased risk of developing wet age-related macular degeneration with the use of oral bisphosphonates (prescribed for osteoporosis prevention). Compared with controls, those using alendronate, ibandronate, and […]
Tara Haelle January 06, 2016 Two thirds of women receiving medication for osteoporosis potentially did not need treatment, according to a retrospective cohort study published online January 4 in JAMA Internal Medicine. In fact, half of these women with possibly inappropriate prescriptions were younger and without risk factors that would have indicated screening, found Joshua […]
December 09, 2013 By Reuters Staff NEW YORK (Reuters) Dec 09 – Merck & Co has agreed to settle hundreds of lawsuits over jaw injuries allegedly caused by the osteoporosis drug Fosamax, lawyers disclosed at a court hearing Monday. Lawyers for Merck and plaintiffs pursuing litigation over the once-blockbuster drug revealed at a court hearing […]
The American Journal of Cardiology, 05/21/2014 Clinical Article Sharma A, et al. – The authors have evaluated incidence of new–onset AF with use of oral and intravenous bisphosphonates through a systematic review and meta–analysis of the literature. pooled data from randomized controlled trials (RCTs) and observational studies suggest that risk of AF is increased by […]
Published: Oct 8, 2013 By Cole Petrochko Full Story: http://www.medpagetoday.com/Endocrinology/Osteoporosis/42142 Action Points Evidence from randomized controlled trials and observational studies suggests a significantly increased risk of atrial fibrillation requiring hospitalization among patients who take bisphosphonates, researchers found. However, there was no increase in risk of stroke or cardiovascular mortality with the use of bisphosphonates. Bisphosphonate […]
MedPageToday.com Published: Apr 18, 2013 | Updated: Apr 19, 2013 By Charles Bankhead , Staff Writer, MedPage Today Story Source Action Points Note that this randomized trial demonstrated that treatment with zoledronic acid (Brand names: Reclast, Zometa/bisphosphonate) increased sclerostin, which may inhibit healthy bone turn-over. Be aware that no clinical outcomes (such as fracture) were […]